IB-T101, a CD70-targeted chimeric antigen receptor therapy, is being studied for relapsed clear cell renal cell carcinoma ...

Beyond research, Germain concludes the conversation by providing helpful insights into the biggest challenges in lymphoma ...

Marlise R. Luskin, MD, MSCE, discusses the trial of tagraxofusp in BPDCN, which showed high response rates and overall survival.

The panelist discusses how, expanding clinical trials, biomarker testing, and financial support improves access to emerging ...

Alexander Spira, MD, PhD, FACP, discusses the PAPILLON trial, including its methods, design, and rationale as well as new data from the study.

PYX-201 has gained FDA fast track designation in recurrent or metastatic head and neck squamous cell carcinoma.

An expert discusses the design and objectives of the PEACE-3 study, which investigates the combination of enzalutamide and ...

A panelist discusses how patient-reported outcomes and real-world evidence contribute valuable insights into the practical impact of these treatments, complementing traditional efficacy measures and ...

The panelist discusses the case of a 60-year-old man diagnosed with unresectable hepatocellular carcinoma (HCC). The patient has a history of metabolic dysfunction-associated steatohepatitis managed ...

An expert discusses how, in third line (3L) therapy, goals shift from optimal disease control to managing treatment-resistant disease while preserving quality of life. Unlike 2L therapy where ...

An expert discusses the patient case of a 65-year-old woman who has presented to the emergency department with abdominal pain. The patient’s previous medical issues include a duodenal ulcer that she ...

During a live event, participating oncologists discuss the role of ctDNA and molecular testing in muscle-invasive bladder ...